ReviewCurrent gastroenterology reports2012
The chronic gastrointestinal consequences associated with campylobacter.
Review in Current gastroenterology reports, 2012. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT02280044 (Double Blind, Placebo-Controlled Trial Assessing the Efficacy of Rifaximin in Preventing Campylobacteriosis in Subjects Challenged With Campylobacter Jejuni), which is not on this map. Cited by 34 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Double Blind, Placebo-Controlled Trial Assessing the Efficacy of Rifaximin in Preventing Campylobacteriosis in Subjects Challenged With Campylobacter Jejuni
Who cites it
34 citing papers in PubMed, 1 synthesis or guideline pooled it, 66 citations in OpenAlex.
- Systematic review and meta-analysis of the proportion of Campylobacter cases that develop chronic sequelae.BMC public health · 2014Pooled it
- Lack of homologous protection against Campylobacter jejuni CG8421 in a human challenge model.Clinical infectious diseases : an official publication of the Infectious Diseases Society of America · 2013Trial
- Mapping the reciprocal interactions between antidepressants and the gut microbiome: novel targets for the personalisation and optimization of drug response.Molecular psychiatry · 2026Review
- Impact of animal socioecology on gut microbial communities: Insights from wild meerkats in the Kalahari.The Journal of animal ecology · 2025Article
- Examination of Methods to Estimate Productivity Losses in an Economic Evaluation: Using Foodborne Illness as a Case Study.PharmacoEconomics · 2025Article
- Treatment heterogeneity of water, sanitation, hygiene, and nutrition interventions on child growth by environmental enteric dysfunction and pathogen status for young children in Bangladesh.PLoS neglected tropical diseases · 2025Article
- Diversity ofmSphere · 2024Article
- Whole-genome sequences ofMicrobiology resource announcements · 2024Article
- Treatment Heterogeneity of Water, Sanitation, Hygiene, and Nutrition Interventions on Child Growth by Environmental Enteric Dysfunction and Pathogen Status for Young Children in Bangladesh.medRxiv : the preprint server for health sciences · 2024Article
- Modulation of innate lymphoid cells by enteric bacterial pathogens.Frontiers in immunology · 2023Review
- Genomic insights into zoonotic transmission and antimicrobial resistance in Campylobacter jejuni from farm to fork: a one health perspective.Gut pathogens · 2022Review
- Development and validation of a CRISPR interference system for gene regulation in Campylobacter jejuni.BMC microbiology · 2022Article
- Controlled Human Infection Models To Accelerate Vaccine Development.Clinical microbiology reviews · 2022Review
- Chronic Gastrointestinal and Joint-Related Sequelae Associated with Common Foodborne Illnesses: A Scoping Review.Foodborne pathogens and disease · 2020Article
- The Campylobacter jejuni helical to coccoid transition involves changes to peptidoglycan and the ability to elicit an immune response.Molecular microbiology · 2019Article
- Heat-Stable Enterotoxins of EnterotoxigenicToxins · 2019Review
- Motility and biofilm formation of the emerging gastrointestinal pathogen Campylobacter concisus differs under microaerophilic and anaerobic environments.Gut microbes · 2019Article
- Update on Campylobacter vaccine development.Human vaccines & immunotherapeutics · 2019Review
- Article
- Post-infectious sequelae after Campylobacter enteric infection: a pilot study in Maricopa County, Arizona, USA.Pilot and feasibility studies · 2018Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors at 3 institutions in 2 countries.
Funding
Abstract
Campylobacteriosis is a leading cause of acute infectious diarrhea in the developing world, where it causes considerable mortality, and in developed countries, where it accounts for significant healthcare and other costs. Evidence has emerged from basic science, clinical, and epidemiological domains that suggests that Campylobacter infection is not limited to acute illness but is also involved in the development of well-described extraintestinal sequelae, such as the Guillain-Barré syndrome and reactive arthritis, and may also contribute to the pathogenesis of chronic gastrointestinal conditions. This review will focus on the role of Campylobacter infection as a risk factor for the development of chronic gastrointestinal sequelae, such as functional gastrointestinal disorders, with which irritable bowel syndrome has been most frequently associated, inflammatory bowel disease, and celiac disease.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.